Latest Period
Q1 2026
Security Snapshot
Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share (ESLA) Institutional Ownership
CUSIP: 297584104
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
16
Shares (Excl. Options)
5,178,824
Price
$1.06
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ESLA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,178,824
- Total 13F value
- $5,489,554
- Portfolio coverage rank
- 0%
- Share change
- +4,180,594
- Value change
- +$4,327,926
- Number of holders
- 16
- Shares outstanding
- 42,846,597
- SEC-reported price per share
- $1.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ESLA - Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 297584104.
- 16 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 15 to 16 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,559,085 to $5,489,554.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 16 institutions filings for Q1 2026.
Security key
297584104
Latest holder period
Q1 2026
13F holders
16
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
ESLA full holder history
Estrella Immunopharma, Inc. SEC filings
Estrella Immunopharma, Inc. company facts
Estrella Immunopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 297584104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
ESLA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 10% | $7,490,656 | 4,280,375 | Armistice Capital, LLC | 31 Mar 2026 |
As of 31 Mar 2026, 16 institutional investors reported holding 5,178,824 shares of Estrella Immunopharma, Inc. - Common Stock, par value $0.0001 per share (ESLA). This represents 12% of the company’s total 42,846,597 outstanding shares.
13F concentration
Top 22 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
12%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9.6% | 4,099,000 | 0.14% | $4,344,940 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.89% | 382,469 | 0% | 0% | $405,417 |
| WELLS FARGO & COMPANY/MN | 0.62% | 264,388 | 0% | $280,251 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.37% | 157,485 | +43% | 0% | $166,933 |
| VANGUARD FIDUCIARY TRUST CO | 0.15% | 64,921 | 0% | 0% | $68,816 |
| RENAISSANCE TECHNOLOGIES LLC | 0.15% | 62,795 | -49% | 0% | $66,563 |
| STATE STREET CORP | 0.1% | 43,252 | 0% | 0% | $45,847 |
| BlackRock, Inc. | 0.09% | 39,890 | +51% | 0% | $42,283 |
| NORTHERN TRUST CORP | 0.05% | 19,624 | 0% | 0% | $20,801 |
| US BANCORP \DE\ | 0.04% | 16,904 | 0% | $17,918 | |
| UBS Group AG | 0.04% | 15,079 | +373% | 0% | $15,983 |
| ROYAL BANK OF CANADA | 0.02% | 6,600 | 0% | 0% | $7,000 |
| Tower Research Capital LLC (TRC) | 0.01% | 4,859 | 0% | $5,151 | |
| TORONTO DOMINION BANK | 0% | 1,089 | 0% | $1,154 | |
| WOLVERINE ASSET MANAGEMENT LLC | 0% | 468 | 0% | $496 | |
| MORGAN STANLEY | 0% | 1 | -100% | 0% | $1 |
| JANE STREET GROUP, LLC | 0% | 0 | -100% | $0 | |
| MARSHALL WACE, LLP | 0% | 0 | -100% | $0 | |
| Quadrature Capital Ltd | 0% | 0 | -100% | $0 | |
| XTX Topco Ltd | 0% | 0 | -100% | $0 | |
| CITADEL ADVISORS LLC | 0% | 0 | -100% | $0 | |
| BANK OF AMERICA CORP /DE/ | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,178,824 | $5,489,554 | +$4,327,926 | $1.06 | 16 |
| 2025 Q4 | 999,605 | $1,559,085 | +$479,373 | $1.56 | 15 |
| 2025 Q3 | 743,186 | $878,824 | +$136,305 | $1.15 | 13 |
| 2025 Q2 | 634,819 | $559,552 | +$21,644 | $0.96 | 11 |
| 2025 Q1 | 613,145 | $568,449 | +$294,571 | $0.93 | 11 |
| 2024 Q4 | 292,276 | $341,108 | +$108,454 | $1.20 | 11 |
| 2024 Q3 | 200,095 | $232,108 | +$69,208 | $1.16 | 10 |
| 2024 Q2 | 123,037 | $129,188 | -$16,862 | $1.05 | 7 |
| 2024 Q1 | 135,217 | $165,522 | +$8,208 | $1.24 | 6 |
| 2023 Q4 | 128,581 | $143,186 | +$143,186 | $1.11 | 7 |